Clinical Colon Cancer 2007


Abby Siegel MD


COLON CANCER


- 1. Epidemiology
- 2. Risk factors
- 3. Manifestations
- 4. Treatment

1. EPIDEMIOLOGY

- Colorectal cancer is the third most common cancer in the United States
- About 150,000 new cases/year
- Most cases in people over 50







EPIDEMIOLOGY

- Incidence rates high in U.S., Europe, Australia
- Increasing in Japan
- Low in China, Africa

EPIDEMIOLOGY

- Changes in incidence rates over time and with migration may indicate role of environmental factors

2. RISK FACTORS: Protective

- Folic acid
- Exercise
- NSAIDS
- ? Calcium/Vitamin D
- ? Fiber

NSAIDS

- 1) Cox-1 and Cox-2 inhibition
 - -Aspirin, Ibuprofen
 - -Bleeding risk
- 2) Selective Cox-2 inhibition
 - -Rofecoxib (Vioxx),
 - -Celecoxib (Celebrex)
 - -Thrombosis risk

RISK FACTORS:

Increased risk with...


- -Advanced age
- -Inflammatory bowel disease
- -Consumption of high-fat diet and red meat
- -Personal or family history of colon cancer


FAMILIAL SYNDROMES


- HNPCC
 - Hereditary non-polyposis colon cancer
- APC
 - Adenomatous polyposis coli
- Both usually autosomal dominant


HNPCC (Lynch Syndrome) Hereditary Non-Polyposis Colon Cancer

- 2-5% of colon cancers
- Caused by mutations in mismatch repair genes
- Tend to present in the right colon
- Often associated with endometrial cancer in women
- Start screening at age 21











APC Adenomatous Polyposis Coli

- Less than 1% of colon cancers
- Caused by mutation of APC gene (5q21)
- Also associated with duodenal cancers, desmoid tumors, "CHRPE" (congenital hypertrophy of the retinal pigment)
- Start screening at puberty








3. MANIFESTATIONS

- 1. Growth of cancer at primary site
- 2. Metastatic spread





MANIFESTATIONS

- 1. Growth of cancer at primary site
 - a. Asymptomatic/screening
 - b. Right sided syndrome
 - c. Left sided syndrome

MANIFESTATIONS

- 1. Growth of cancer at primary site
 - i. Asymptomatic
 - Detected by screening test
 - Fecal occult blood
 - Sigmoidoscopy
 - Colonoscopy
 - "Virtual" colonoscopy
 - Molecular techniques






Screening summary

- Average risk: colonoscopy every 10 years over age 50
- Family history: colonoscopy 10 years before index case
- Dysplastic polyps: repeat colonoscopy after 3 years

Screening, continued...

- APC: annual flexible sigmoidoscopy starting at age 11, colectomy when polyps develop
- HNPCC: colonoscopy at age 21, then every 1-2 years
- Inflammatory bowel disease: start 8 years after pancolitis, 12 years after distal disease





MANIFESTATIONS


- 1. Growth of cancer at primary site ii. Right sided syndrome
 - a) Ascending colon has thin wall, large diameter, distensible
 - b) Liquid fecal stream
 - c) Chronic blood loss results in iron deficiency anemia***
 - d) Obstruction unlikely


MANIFESTATIONS


- 1. Growth of cancer at primary site iii. Left sided syndrome
 - a) Descending colon wall thicker, less distensible
 - b) More solid fecal stream
 - c) Tumors tend to infiltrate
 - d) Bright red blood more common
 - e) Obstruction more common












MANIFESTATIONS Metastatic Spread 1. Lymphatics Mesenteric nodes Virchow's node 2. Hematogenous spread Liver via portal circulation





LIVER METASTASES

MANIFESTATIONS

- 1. Pain (stretching capsule)
- 2. Hepatomegaly, nodularity
- 3. Elevated liver function tests

4. TREATMENTS


- 1. Surgery
- -Localized disease (Stage I, II, III)
- -Try to remove isolated metastases
- 2. Radiation therapy
- -Rectal cancer-helps prevent local recurrence
- 3. Pharmaceuticals
 - -Stage III and IV disease

TREATMENT: Pharmaceuticals

- 1. 5-Fluorouracil
 - pyrimidine antimetabolite
- 2. Irinotecan
 - topoisomerase inhibitor prevents re-ligation after cleavage of DNA by topoisomerase I
- 3. Oxaliplatin
 - alkylating agent, causes formation of bulky DNA adducts

Exciting new biologics...


- 4. Bevacizumab
 - -Antibody against VEGFR
 - -May block angiogenesis and also stabilize leaky vasculature
- 5. Cetuximab, Panitumomab
 - -Antibody against EGFR
 - -Binds to EGF receptor on tumor cells and prevents dimerization and cell signaling






TREATMENT: Metastatic disease

- Systemic chemotherapy now has improved survival for those with metastatic disease to about 2 years
- We now sometimes treat neoadjuvantly (before surgery), shrinking metastases and then surgically removing them
- This is important, because some of these "isolated metastases" patients are cured!





Conclusions:

- Know HNPCC and APC—these may help you prevent cancers in others
- Understand how colon cancer commonly presents (right versus left-sided), and common sites of spread
- Think about colon (or other GI) cancer in an older person with iron-deficiency anemia—don't just give them iron!
- Don't give up on those with metastatic disease with new treatment options and occasionally cures

- My email:
- aas54@columbia.edu
- Many thanks to Tom Garrett for many slides!